The above considerations based on the PARP inhibitor clinical experience, point to a real need to better identify strategies that can lead to enhanced anti-tumor efficacy with DDR inhibitor-chemotherapy combinations while mitigating the unacceptable normal tissue toxicities. Here, PARP1 is linked to neoplasm.